Parschauer Karah Herdman 4

What Happened Karah Parschauer, Executive Vice President and Chief Legal Officer of Ultragenyx Pharmaceutical Inc. (RARE), received two restricted stock unit (RSU) awards on 2026-04-16 totaling 78,855 RSUs (28,895 RSUs + 49,960 RSUs). Both awards are reported as acquisitions at $0.00 (standard for equity awards); no cash was paid. This is an equity grant (award), not a market purchase or sale.

Key Details

• Transaction date: 2026-04-16; filing date: 2026-04-20 (filing appears timely).
• Reported amounts: 28,895 RSUs (A) and 49,960 RSUs (A, listed as a derivative).
• Reported price: $0.00 per RSU (award/grant).
• Vesting: RSUs vest 1/4th on each anniversary of the grant and fully vest on the fourth anniversary (per footnote F1).
• Footnotes: F2 notes the reported amounts include previously reported shares underlying RSUs subject to vesting; F3 describes a separate option vesting schedule (monthly after the first anniversary) though no option exercise is reported here.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context

• These are time-based RSU awards that convert into company shares only as they vest; the derivative listing simply reflects rights to future shares rather than immediate share ownership. Such grants are common compensation for executives and are neither an open-market purchase (a potential bullish signal) nor a sale.